Items Tagged ‘Soft Tissue Sarcomas’

November 7th, 2016

Chemotherapy Before Surgery Improves Treatment of Sarcoma

By

For patients with localized soft-tissue sarcoma of the trunk or extremities who are high risk for relapse, the use of anthracycline plus ifosfamide chemotherapy prior to surgery appears to improve survival. Chemotherapy administered before surgery is called neoadjuvant therapy and has not previously been demonstrated to improve outcomes in soft tissue sarcoma (STS). Soft tissue […]

View full entry

Tags: anthracycline, dacarbazine, epirubicin, for undifferentiated pleomorphic sarcoma, gemcitabine, ifosfamide, leiomyosarcoma, malignant peripheral nerve sheath tumors, neoadjuvant therapy, News, Sarcoma, soft tissue sarcoma


February 4th, 2016

Halaven Approved for Liposarcoma

By

The United States Food and Drug Administration (FDA) has approved the chemotherapy agent Halaven (eribulin) for the treatment of liposarcoma. It’s the first drug approved for liposarcoma that has demonstrated an improvement in overall survival. Halaven is already approved for the treatment of advanced breast cancer. The approval indication for Halaven in the treatment of […]

View full entry

Tags: eribulin, fda, Halaven, liposarcoma, News, Sarcoma, soft tissue sarcoma, Soft Tissue Sarcomas, STS


November 2nd, 2015

Yondelis® Approved for Treatment of Soft Tissue Sarcoma

By

The United States Food and Drug Administration (FDA) approved the chemotherapy agent, Yondelis® (trabectedin), for the treatment of liposarcoma and leiomyosarcoma—two types of soft-tissue sarcomas.1 The approval of Yondelis is for patients whose cancer is not able to be removed by surgery and/or has spread to distant sites in the body. This treatment is approved […]

View full entry

Tags: advanced, leimyosarcoma, liposarcoma, News, Sarcoma, Soft Tissue Sarcomas, trabectedin, yondelis


October 20th, 2015

Yondelis® Bests Standard Therapy in Liposarcoma and Leiomyosarcoma

By

The chemotherapy agent, Yondelis® (trabectedine), improves outcomes compared to the standard agent, DTIC (dacarbazine), in patients with advanced liposarcoma or leiomyosarcoma that has recurred or progressed following prior therapies. These results were recently published as a “rapid communication” in the Journal of Clinical Oncology. Liposarcoma and leiomyosarcoma are both types of soft-tissue sarcomas.  Soft tissue […]

View full entry

Tags: dacarbazine, DTIC, leiomyosarcoma, liposarcoma, News, Sarcoma, Soft Tissue Sarcomas, trabectedine, yondelis


June 11th, 2015

Longer Overall Survival for Patients with Soft Tissue Sarcoma Treated with Halaven®

By

Halaven® (eribulin) may extend overall survival in patients with previously treated, advanced soft tissue sarcoma (STS). These findings were presented at 2015 Annual Meeting of the American Society of Clinical Oncology (May 29–June 2, Chicago, Illinois) and published in the Journal of Clinical Oncology.[1] Soft tissue sarcomas are cancers that affect the connective and supportive […]

View full entry

Tags: ADI, adipocytic sarcoma, Halaven, leiomyosarcoma, LMS, News, Sarcoma, soft tissue sarcoma, Soft Tissue Sarcomas, STS


February 4th, 2015

YONDELIS® (trabectedin) for the Treatment of Patients with Advanced Soft Tissue Sarcoma

By

The U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for YONDELIS® (trabectedin) to treat patients with advanced soft tissue sarcoma (STS), including liposarcoma and leiomyosarcoma subtypes. YONDELIS® is a novel, multimodal, synthetically produced antitumor agent, originally derived from the sea squirt, Ecteinascidia turbinata. The anti-cancer medicine works […]

View full entry

Tags: General Sarcoma, News, Sarcoma, Soft Tissue Sarcomas, soft tissue sardcoma, trabectedin, yondelis


June 27th, 2014

Torisel Improves Event-Free Survival in Rhabdomyosarcoma Patients

By

In a study presented at the 2014 American Society of Clinical Oncology® meeting in Chicago, researchers reported that Torisel® (temsirolimus) added to a chemotherapy regimen improved event-free survival in young patients with rhabdomyosarcoma. Rhabdomyosarcoma is a rare cancer that develops in the cells that eventually become skeletal muscles, those used for voluntary movements of the […]

View full entry

Tags: News, rhabdomyosarcoma, Sarcoma, Soft Tissue Sarcomas, torisel


June 13th, 2012

Regorafenib May Expand GIST Treatment Options

By

Among patients with gastrointestinal stromal tumors (GIST) that worsen in spite of standard treatment, the investigational drug regorafenib delays cancer progression. These results—from a Phase III clinical trial—were presented at the 2012 Annual Meeting of the American Society of Clinical Oncology. GIST is a type of soft tissue sarcoma that develops in the stomach, small […]

View full entry

Tags: General Sarcoma, News, Sarcoma, Soft Tissue Sarcomas